Further research is needed to validate our findings in a larger cohort, and to examine whether the infiltration of both tumour and stromal CD8+ immune cells can be used as a biomarker during immune checkpoint inhibition in NSCLC patients. The gene discussed is CD8A; the disease is neoplasm.